Language:English
Language:

Xcessbio

Place your promotion here

You have no items in your shopping cart.

AG-120 (Ivosidenib), IDH1 Inhibitor

AG-120 (Ivosidenib), IDH1 Inhibitor

$129.00
A potent, selective and reversible inhibitor of IDH1 in clinical trials.
Catalog No. Unit Price Qty
M60318-2s 2 mg solid $129.00

Details

Product Information
Molecular Weight: 582.96
Formula: C28H22ClF3N6O3
Purity: ≥98%
CAS#: 1448347-49-6
Solubility: DMSO up to 100 mM; EtOH up to 100 mM
Chemical Name: (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

AG-120 (Ivosidenib) is a potent, selective and reversible inhibitor of IDH1 with IC50 < 100 nM. It has been shown to lower 2-HG levels and restore cellular differentiation in IDH1-mutant primary human blast cells cultured ex vivo. In phase I clinical trials targeting patients with IDH1-mutated, relapsed and/or refractory (R/R) AML or untreated AML not eligible for standard of care or R/R MDS, AG-120 is well tolerated to date (10/2015) and MTD was not reached. Overall response rate is 35% including 12 CRs.

How to Use:

In vitro: AG-120 was used at 1 µM in vitro and cellular assays.
In vivo:
AG-120 was dosed orally to mice bearing IDH1 mutant tumors at 150 mg/Kg once per day.

Reference:

  • 1. Erica Hansen, et al. AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo. (2014) Blood. 124:3734
  • 2. Kc B, et al. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120. (2016) Clin Lymphoma Myeloma Leuk. In press.



Products are for research use only. Not for human use. 


Description

Details

Product Information
Molecular Weight: 582.96
Formula: C28H22ClF3N6O3
Purity: ≥98%
CAS#: 1448347-49-6
Solubility: DMSO up to 100 mM; EtOH up to 100 mM
Chemical Name: (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

AG-120 (Ivosidenib) is a potent, selective and reversible inhibitor of IDH1 with IC50 < 100 nM. It has been shown to lower 2-HG levels and restore cellular differentiation in IDH1-mutant primary human blast cells cultured ex vivo. In phase I clinical trials targeting patients with IDH1-mutated, relapsed and/or refractory (R/R) AML or untreated AML not eligible for standard of care or R/R MDS, AG-120 is well tolerated to date (10/2015) and MTD was not reached. Overall response rate is 35% including 12 CRs.

How to Use:

In vitro: AG-120 was used at 1 µM in vitro and cellular assays.
In vivo:
AG-120 was dosed orally to mice bearing IDH1 mutant tumors at 150 mg/Kg once per day.

Reference:

  • 1. Erica Hansen, et al. AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo. (2014) Blood. 124:3734
  • 2. Kc B, et al. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120. (2016) Clin Lymphoma Myeloma Leuk. In press.



Products are for research use only. Not for human use. 


Reviews

Write Your Review

How do you rate this product? *

Price:
Value:
Quality: